South Wales, Sept. 24 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "Venoflo" on Sept. 5. The details about the trademark application no. UK00004260079 published in the journal no. 2025/038 (Sept. 19).
Desciphar Pharma Limited filed the trademark application for the below mentioned good(s)/service(s).
Class 5 : Pharmaceutical preparations for the prevention of ocular diseases; Pharmaceutical preparations for the prevention of ocular disorders; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of cardiovascular disease; Diuretics; Diuretic pharmaceutical preparations; Diuretic preparations; Oedema pharmaceutical preparations, Pharmaceutical preparations for the treatment of central nervous system[CNS] diseases; Pharmaceutical preparations for the treatment of digestive diseases; Pharmaceutical preparations for the treatment of diseases caused by bacteria; Pharmaceutical preparations for the treatment of pulmonary diseases; Pharmaceutical preparations for the treatment of diseases of the endocrine system; Pharmaceutical preparations for the treatment of diseases of the genitourinary system; Pharmaceutical preparations for the treatment of diseases of the metabolic system; Pharmaceutical preparations for the treatment of diseases of the musculoskeletal system; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for the treatment of disorders of the endocrine system; Pharmaceutical preparations for the treatment of disorders of the genitourinary system; Pharmaceutical preparations for the treatment of disorders of the metabolic system; Pharmaceutical preparations for the treatment of epilepsy; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of gout; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of kidney disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of Musculoskeletal disorders; Pharmaceutical preparations for the treatment of musculoskeletal disorders; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for the treatment of Parkinsons disease; Pharmaceutical preparations for the treatment of tumours; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of worms in pets; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating arthritis; Pharmaceutical preparations for treating asthma; Pharmaceutical preparations for treating chloasma; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating digestive system disorders; Pharmaceutical preparations for treating gastrointestinal disorders; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating hypoglycemia; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for treating metabolic disorders; Pharmaceutical preparations for treating peripheral nervous system disorders; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical preparations for treating rheumatological diseases; Pharmaceutical preparations for treating sensory organ disorders; Pharmaceutical preparations for treating skeletal diseases; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sports injuries; Pharmaceutical preparations for use in hematology; Pharmaceutical preparations for use in ophthalmology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for veterinary use; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations for chloasma; Pharmaceutical products for ophthalmological use; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral diseases; Pharmaceutical products for treating respiratory diseases; Pharmaceuticals; Pharmaceuticals and natural remedies; Preparations of microorganisms for medical and veterinary use; Preparations of microorganisms for medical or veterinary use; Preparations of trace elements for human and animal use; Pharmaceutical preparations for reducing bleeding.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004260079
Disclaimer: Curated by HT Syndication.
